"10.1371_journal.pone.0088472","plos one","2014-02-06T00:00:00Z","Niklas Bergvall; Charles Makin; Raquel Lahoz; Neetu Agashivala; Ashish Pradhan; Gorana Capkun; Allison A Petrilla; Swapna U Karkare; Catherine Balderston McGuiness; Jonathan R Korn","Novartis Pharma AG, Basel, Switzerland; IMS Health, Plymouth Meeting, Pennsylvania, United States of America; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America","Conceived and designed the experiments: NB CM RL NA AP GC AAP SUK CBM JRK. Analyzed the data: NB CM AAP SUK CBM JRK. Contributed reagents/materials/analysis tools: NB CM RL AAP SUK CBM JRK. Wrote the paper: NB CM RL NA AP GC AAP SUK CBM JRK. Reviewed the paper: NB CM RL NA AP GC AAP SUK CBM JRK. Interpreted results: NB CM RL NA AP GC AAP SUK CBM JRK.","The authors have the following interests: The analyses for this study were funded by Novartis Pharma AG, the employer of NB, RL, NA, AP and GC. The following authors have a share in Novartis: NB, RL, NA, AP and GC. Fingolimod is a Novartis product. CM, AAP, SUK, CBM and JRK are employed by IMS Health. There are no further patents, products in development or marketed products to declare. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","02","Niklas Bergvall","NB",10,TRUE,10,NA,6,10,TRUE,TRUE,FALSE,0,NA,FALSE
